Skip to main content
SpringerLink
Log in

Renal Osteodystrophy: Prevention and Management

  • Chapter
Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS

  • 296 Accesses

Abstract

Renal osteodystrophy is the term used to describe the complex abnormalities of bone that may occur, to variable extents, in many patients with renal disease. The spectrum of disorders of the skeleton in these patients is broad and extends from states of accelerated bone turnover with increased bone resorption due to excessive levels of parathyroid hormone (PTH) (osteitis fibrosa) to disorders of bone mineralization (osteomalacia) and other states of decreased bone turnover (adynamic bone). In addition, osteosclerosis, bone cysts, loss of bone mineral, and skeletal fractures may occur. The pathogenesis of these abnormalities has been the subject of intense investigation for the past two decades; the consequences of decreased renal function that give rise to these disorders of bone have been characterized and serve as the basis for a rational approach to the prevention and therapy of the skeletal abnormalities of renal dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood Celia, Manuel A, Saiphoo C, Fenton SS, Segre G: The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int 43: 436–442, 1993.

    Article  PubMed  CAS  Google Scholar 

  2. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid mediated osseus abnormalities in uremia. J Clin Endocrinol Metab 75: 145–150, 1992.

    Article  PubMed  CAS  Google Scholar 

  3. Slatopolsky E, Caglar S, Pennell JP, Taggart J, Canterbury J, Reiss E, Bricker NS: On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J Clin Invest 50: 492–499, 1971.

    Article  PubMed  CAS  Google Scholar 

  4. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake. Kidney Int 2: 147–151, 1972

    Article  PubMed  CAS  Google Scholar 

  5. Tanaka Y, DeLuca HF: The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 159: 566–574, 1973.

    Article  Google Scholar 

  6. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259: F432–F437, 1990.

    PubMed  CAS  Google Scholar 

  7. Aparicio M, Combe C, Lafage MH, De Precigout V, Potaux

    Google Scholar 

  8. L, Bouchet JA: In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol. Nephron 63: 122–123, 1992.

    Google Scholar 

  9. Fugakawa M, Kurokawa K: Mild dietary phosphorus restriction directly prevents enhanced parathyroid hormone secretion and synthesis and proliferation of parathyroid cells in chronic renal failure in rats. J Am Soc Nephrol 3: 703, 1992.

    Google Scholar 

  10. Delmez JA, Slatopolsky E: Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303–317, 1992.

    PubMed  CAS  Google Scholar 

  11. Portale AM, Booth BE, Halloran BP, Morris RC: Effect of dietary phosphorus on circulating concentration of 1,25(OH)2D3 and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73: 1580–1589, 1984.

    Article  PubMed  CAS  Google Scholar 

  12. Kaehny W, Hegg A, Alfrey A: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296: 1389–1390, 1977.

    Article  PubMed  CAS  Google Scholar 

  13. Platts MM, Goode GC, Hislop JS: Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br Med J 2: 657660, 1977.

    Google Scholar 

  14. Winney RJ, Cowie JF, Robson JS: Role of plasma aluminum in the detection and prevention of aluminum toxicity. Kidney Int 18:S-91–S-95, 1986.

    Google Scholar 

  15. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS: Reduction of dietary phosphorus absorption by phosphorus binders. J Clin Invest 83: 66–73, 1989.

    Article  PubMed  CAS  Google Scholar 

  16. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate is an effective phosphate binder in dialysis patients. N Engl J Med 315: 157161, 1986.

    Google Scholar 

  17. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J: Long term effects of calcium carbonate and 2,5 meq/liter calcium dialysate on mineral metabolism. Kidney Int 36: 897–903, 1989.

    Article  PubMed  CAS  Google Scholar 

  18. Delmez JA, Tindira CA, Windus DW, Norwood KY, Giles KS, Nighswander TL, Slatopolsky EL: Calcium acetate as phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3: 96–102, 1992.

    PubMed  CAS  Google Scholar 

  19. Caravaca F, Santos I, Cuberoj J, Esparragp JF, Arrobas M, Pizarro JL, Robles R, Sanches-Casado E: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 60: 423–427, 1992.

    Article  PubMed  CAS  Google Scholar 

  20. Hwang S-J, Lai Y-H, Chen H-C, Tsai J-H: Comparison of the effects of calcium carbonate and calcium acetate on zinc tolerance test in hemodialysis patients. Am J Kidney Dis 19: 57–60, 1992.

    PubMed  CAS  Google Scholar 

  21. Mai L, Emmett M, Sheikh MS, Santa Ana CA, Schiller LR, Fordtran JS: Calcium acetate an effective phosphorus binder in patients with renal failure. Kidney Int 36: 690–695, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Froment DP, Molitoris Ba, Buddington B, Miller N, Alfrey AC: Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int 36: 978–984, 1989.

    Article  PubMed  CAS  Google Scholar 

  23. O’Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V: Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphatemia. Lancet 1: 880–882, 1986.

    Article  PubMed  Google Scholar 

  24. Moriniere PH, Fournier A, Lefton A, Herve M, Sebert JL, Gregoire I, Bataille P, Fueris J: Comparison of 1-a OH vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39: 309–315, 1985.

    Article  PubMed  CAS  Google Scholar 

  25. Moriniere PH, Boudailliez N, Hocine CH, Belbrik S, Renaud H, Westeel PF, Cohen Solal ME, Fournier A: Prevention of osteitis fibrosa, aluminum bone disease and soft tissues calcification in dialysis patients: a long term comparison of moderate doses of oral calcium ± Mg(OH)Z versus Al(OH)3 ± la OH vitamin D3. Nephrol Dial Transplant 4: 1045–1053, 1989.

    PubMed  CAS  Google Scholar 

  26. Moriniere PH, Vinatier I, Westeel PF, Cohen Solal ME, Belbrik S, Abdulmassih Z, Lefion P, Roche D, Fournier A: Magnesium hydroxide as a complementary aluminum free phosphate binder to high doses of oral calcium in uremic patients on chronic hemodialysis: lack of deleterious effect on bone mineralization. Nephrol Dial Transplant 3: 651–656, 1988.

    PubMed  CAS  Google Scholar 

  27. Wilson L, Felsenfeld A, Drezner MK, Llach F: Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. Kidney Int 27: 565, 1985.

    Article  PubMed  CAS  Google Scholar 

  28. Gray R, Boyle I, DeLuca HF: 1971. Vitamin D metabolism: the role of kidney tissue. Science 172: 1232–1234, 1971.

    Google Scholar 

  29. Brown EM, Wilkson RE, Eastman RC, Pallotta J, Marynick SP: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54: 172–179, 1982.

    Article  PubMed  CAS  Google Scholar 

  30. Delmez AJ, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E: Parathyroid hormone suppression by intrave nous 1,25-dihydroxyvitamin D: a role for increased sensitivity to calcium. J Clin Invest 83: 1349–1355, 1989.

    Article  PubMed  CAS  Google Scholar 

  31. Okazaki T, Igarashi T, Kronenberg HM: 5’-Flanking region of the parathyroid hormone gene mediates negative regulation by 1,25(OH)2D3. J Biol Chem 263: 2203–2208, 1988.

    PubMed  CAS  Google Scholar 

  32. Kremer R, Bolivar I, Goltzman D, Hendy GN: Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 125: 935–941, 1989.

    Article  PubMed  CAS  Google Scholar 

  33. Korkor AB: Reduced binding of [3H] 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316: 1573–1577, 1987.

    Article  PubMed  CAS  Google Scholar 

  34. Somerville PJ, Kaye M: Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites. Kidney Int 14: 245–254, 1978.

    Article  PubMed  CAS  Google Scholar 

  35. Massry SG, Stein R, Garty J, Aruff AI, Coburn JW, Norman AW, Friedler RM: Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25(OH)2D3. Kidney Int 9: 467–474, 1976.

    Article  PubMed  CAS  Google Scholar 

  36. Kaye M, Chatterjee G, Cohen GF, Borra S, Sarar S: Arrest of hyperparathyroid bone disease with dihydrotachysterol in patients undergoing chronic hemodialysis. Ann Intern Med 73: 225–233, 1970.

    Article  PubMed  CAS  Google Scholar 

  37. Kaye M, Sagar S: Effect of dihydrotachysterol on calcium absorption in uremia. Metabolism 21: 815–824, 1972.

    Article  PubMed  CAS  Google Scholar 

  38. Witmer G, Margolis A, Fontaine O, Fritsch J, Lenoir G, Broyer M, Balsan S: Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 10: 395–408, 1976.

    Article  PubMed  CAS  Google Scholar 

  39. Recker R, Schoenfeld P, Letten J, Slatopolsky E, Goldsmith R, Brickman A: The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 138: 857–863, 1978.

    PubMed  Google Scholar 

  40. Brickman AS, Sherrard DJ, Jowsey J, Singer FR, Baylink DJ, Maloney N, Massry SG, Norman AW, Coburn JW: 1,25dihydroxycholecalciferol: effect on skeletal lesions and plasma parathyroid hormone in uremic osteodystrophy. Arch Intern Med 134: 883–888, 1974.

    Article  PubMed  CAS  Google Scholar 

  41. Silverberg DS, Bettcher KB, Dossetor JB, Overton TR, Holick MR, DeLuca HF: Effect of 1,25dihydroxycholecalciferol in renal osteodystrophy. Can Med Assoc J 112: 190–195, 1975.

    PubMed  CAS  Google Scholar 

  42. Baker LRI, Abrams SML, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH: 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 35: 661–669, 1989.

    Article  PubMed  CAS  Google Scholar 

  43. Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with pre-dialysis chronic renal failure. J Clin Endocrinol Metab 67: 661–669, 1988.

    Article  Google Scholar 

  44. Christiansen CL, Rodbro P, Christiansen MS, Hartnack B, Transbol I: Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferal in chronic renal failure. Lancet 2: 700–703, 1978.

    Article  PubMed  CAS  Google Scholar 

  45. Coen G, Mazzaferro S, Bonucci E, Ballanti P, Massimetti C, Donato G, Landi A, Smacchi A, Della Rocca C, Cinotti GA: Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte Metab 12: 375–382, 1986.

    PubMed  CAS  Google Scholar 

  46. Baker LRI, Abrams SML, Roe CJ, Faugere M-C, Fanti P, Subayti Y, Malluche HH: Early therapy of renal bone disease with calcitriol: a prospective double-blind study. Kidney Int 36 (S27): S140 - S142, 1989.

    Google Scholar 

  47. Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33: 98–102, 1990.

    PubMed  CAS  Google Scholar 

  48. Massry SG, Goldstein DA, Malluche HH: Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Kidney Int 19: 409–418, 1980.

    Article  Google Scholar 

  49. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136–2143, 1984.

    Article  PubMed  CAS  Google Scholar 

  50. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274–279, 1989.

    Article  PubMed  CAS  Google Scholar 

  51. Tsukamoto Y, Nomura M, Maurno F: Pharmacological parathyroidectomy by oral 1,25(oh)2D, pulse therapy. Nephron 51: 130–131, 1989.

    Article  PubMed  CAS  Google Scholar 

  52. Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F: The “oral 1,25(OH)2D3 pulse therapy” in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57: 2328, 1991.

    Article  Google Scholar 

  53. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 19: 540–545, 1992.

    PubMed  CAS  Google Scholar 

  54. Reichel H, Szabo A, Uhl J, Resian S, Schmitz A, SchmidtGayk H, Ritz E: Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int 44: 1259–1265, 1993.

    Article  PubMed  CAS  Google Scholar 

  55. Fukada N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436 1443, 1993.

    Google Scholar 

  56. Walling MW: Intestinal Ca and phosphate transport: differential responses of vitamin D3 metabolites. Am J Physiol 233: E488 - E494, 1977.

    PubMed  CAS  Google Scholar 

  57. Ott SM, Maloney NA, Coburn JW, Alrey AC, Sherrard DJ: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 307: 709–713, 1982.

    Article  PubMed  CAS  Google Scholar 

  58. Malluche HH, Faugere MC: Effects of 1,25(OH)2D3 administration on bone in patients with renal failure. Kidney Int 28 (Suppl 29): S48 - S53, 1990.

    Google Scholar 

  59. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 728–732, 1989.

    Article  PubMed  CAS  Google Scholar 

  60. Kopple JD, Coburn JW: Metabolic studies of low protein diets in uremia. II. Calcium, phosphorus and magnesium. Medicine (Baltimore) 52: 597–607, 1973.

    Article  CAS  Google Scholar 

  61. Clarkson EM, Eastwood JB, Koutsaimanis KG, de Wardener HE: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 3: 258–263, 1973.

    Article  PubMed  CAS  Google Scholar 

  62. Andress D, Otts S, Maloney N, Sherrard D: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 31: 468–473, 1985.

    Article  Google Scholar 

  63. Kaye M, D’Amour P, Henderson J: Elective total parathyroidectomy without transplantation in end stage renal disease. Kidney Int 35: 1390–1399, 1989.

    Article  PubMed  CAS  Google Scholar 

  64. Takagi H, Tominaga Y, Uchida K, Yamada N, Kawai M, Kano T, Morimoto T: Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 200: 18–23, 1984.

    Article  PubMed  CAS  Google Scholar 

  65. White JV, LoGerfo P, Fiend C. Weber C: Autologous parathyroid transplantation. Lancet 2: 461, 1983.

    Article  PubMed  CAS  Google Scholar 

  66. Ellis HA: Fate of long-term parathyroid autografts in patients with chronic renal failure treated by parathyroidectomy: a histopathological study of autografts, parathyroid glands and bone. Histopathology 13: 289–309, 1988.

    Article  PubMed  CAS  Google Scholar 

  67. Giangrande A, Castiglioni A, Solbiati L, Maria P: Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 7: 412–421, 1992.

    PubMed  CAS  Google Scholar 

  68. Page B, Zingraff J, Souberbielle JC, Coutris G, Sarfati E, Drueke T, Moreau JF: Correction of severe secondary hyperparathyroidism in two dialysis patients: surgical removal versus percutaneous ethanol injection. Am J Kidney Dis 19: 378–381, 1992.

    PubMed  CAS  Google Scholar 

  69. Takeda S, Michigishi T, Takakura E: Successful ultrasonically guided percutaneous ethanol injection for secondary hyperparathyroidism. Nephrology 62: 100–103, 1992.

    CAS  Google Scholar 

  70. Ellis HA, McCarthy JH, Herrington J: Bone aluminum in haemodialysed patients and in rats injected with aluminum chloride: relationship to impaired bone mineralization. J Clin Pathol 32: 832–844, 1979.

    Article  PubMed  CAS  Google Scholar 

  71. Finch JF, Bergfeld M, Martin KJ, Chan YL, Teitelbaum S, Slatopolsky E: The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia. Kidney Int 30: 318–324, 1986.

    Article  PubMed  CAS  Google Scholar 

  72. Posner AS, Blumenthal NC, Boskey AL: Model of aluminum induced osteomalacia: inhibition of apatite formation and growth. Kidney Int 29: S17 — S19, 1986.

    Google Scholar 

  73. Lieberherr M, Grosse B, Cournot-Witmer G, HermannErlee MPM, Balsan S: Aluminum action on mouse bone cell metabolism and response to PTH and 1,25(OH)2D3. Kidney Int 31: 737–743, 1987.

    Article  Google Scholar 

  74. Goodman WG, Henry DA, Horst R, Nudelman RK, Alfrey AC, Coburn, JW: Parenteral aluminum administration in the dog: II. Induction of osteomalacia and effect on vitamin D metabolism. Kidney Im’ 25: 370–375, 1984.

    Article  CAS  Google Scholar 

  75. Morrissey J, Slatopolsky E: Effect of aluminum on parathyroid hormone secretion. Kidney Int 29:S-41—S-44, 1986.

    Google Scholar 

  76. Alfrey A: Aluminum metabolism. Kidney Int 29: S8 — S11, 1986.

    Google Scholar 

  77. Gonzalez EA, Martin KJ: Aluminum and renal osteodystrophy: a diminishing clinical problem. Trends Endocrinol Metab 3: 371–375, 1992.

    Article  PubMed  CAS  Google Scholar 

  78. Molitoris BA, Froment DH, MacKenzie TA, Huffer WH, Alfrey AC: Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 36: 949–953, 1989.

    Article  PubMed  CAS  Google Scholar 

  79. Cannatta JB, Fernandez-Soto I, Fernandez MMJ, Brock JH, Fernandez MJL, Halls D: The role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int 39: 799–803, 1991.

    Article  Google Scholar 

  80. Nebeker HG, Andress DL, Milliner DS, Ott SM, Alrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW: Indirect methods for the diagnosis of aluminim bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Kidney Int 29 (Suppl 18): S96 — S99, 1986.

    Google Scholar 

  81. Pei Y, Hercz G, Greenwood C, Sherrard D, Segre G, Manuel A, Saiphoo C, Fenton S: Non-invasive prediction of alumi-num bone disease in hemo and peritoneal dialysis patients. Kidney Int 41: 1374–1382, 1992.

    Article  PubMed  CAS  Google Scholar 

  82. Kaehny WD, Alfrey AC, Holman RE, Shorr WJ: Aluminum transfer during hemodialysis. Kidney Int 12: 361–365, 1977.

    Article  PubMed  CAS  Google Scholar 

  83. Milliner DS, Hercz G, Milliner JH, Shinaberger JH, Nissenson A, Coburn JW: Clearance of aluminum by hemodialysis: effect of desferrioxamine. Kidney Int 29:5–100S-103, 1986.

    Google Scholar 

  84. CONSENSUS conference: Diagnosis and treatment of aluminum overload in end stage renal failure patients. Nephrol Dial Transplant Suppl 1: 1–4, 1993.

    Google Scholar 

  85. Swartz RD: Deferoxamine and aluminum removal. Am J Kidney Dis 6: 358–364, 1985.

    PubMed  CAS  Google Scholar 

  86. Olivieri NF, Buncic JR, Chew E, Gallant Tsvi, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314: 869–873, 1986.

    Article  PubMed  CAS  Google Scholar 

  87. Windus DW, Stokes TJ, Julian BA, et al.: Rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 107: 678–680, 1987.

    Article  PubMed  CAS  Google Scholar 

  88. Sherrard DJ, Andress DL: Aluminum-related osteodystrophy. Adv Intern Med 34: 307–324, 1989.

    PubMed  CAS  Google Scholar 

  89. Malluche HH, Monier-Faugere MC: Uremic bone disease: current knowledge, controversial issues, and new horizons. Miner Electrolyte Metab 17: 281–296, 1991.

    PubMed  CAS  Google Scholar 

  90. Molitoris BA, Alfrey AC, Alfrey PS, Miller NL: Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 34: 98–101, 1988.

    Article  PubMed  CAS  Google Scholar 

  91. Delmez J, Weerts C, Lewis-Finch J, Windus D, Slatopolsky E: Accelerated removal of deferoxamine Mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients. Am J Kidney Dis 13: 308–311, 1989.

    PubMed  CAS  Google Scholar 

  92. Weiss LG, Danielson BG, Fellstrom B, Wikstrom B: Aluminum removal with hemodialysis, hemofiltration and hemoperfusion in uremic patients after desferrioxamine infusion. Nephron 51: 325–329, 1989.

    Article  PubMed  CAS  Google Scholar 

  93. Morniere P, Cohen-Solal M, Belbrik S, Boudailliez B, Marie A, Westeel PF, Renaud H, Fievet P, Lalau JD, Sebert JL, Fournier A: Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum Nephron 53: 93–101, 1989.

    Article  Google Scholar 

  94. Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int 42(38):S-62—S-67, 1992.

    Google Scholar 

  95. Cohen-Solal ME, Sebert JL, Boudailliez B, Westeel PF, Moriniere PH, Marie A, Garabedian M, Fournier A: Nonaluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? Bone 13: 1–5, 1992.

    Article  PubMed  CAS  Google Scholar 

  96. De Vernejoul MC, Girot R, Gueris J, Cancela L, Bang S, Bielakoff J, Mautalen C, Goldberg D, Miravet L: Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J Clin Endocrinol Metab 54: 276–281, 1982.

    Article  PubMed  Google Scholar 

  97. Boivin G, Chapuy MC, Baud C, Meunier Pk Fluoride content in human iliac bone. Results in controls, patients with fluorosis, and osteoporotics treated with fluoride. J Bone Miner Res 3: 497–502, 1988.

    Article  PubMed  CAS  Google Scholar 

  98. Vincenti F, Arnaud SB, Recker R, Genant H, Amend W, Feduska N, Salvatierra O: Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 25: 677–682, 1984.

    Article  PubMed  CAS  Google Scholar 

  99. Morton AR, Hercz G: Hypercalcemia in dialysis patients: 1991. Comparison of diagnostic methods. Dial Transplant 20: 661–694, 1991.

    Google Scholar 

  100. Geyko F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasswa Y, Shirahama T, Cohen AS, Schmid K: A new form of amyloid protein associated with chronic hemodialysis was identified as 13–2 microglobulin. Biochem Biophys Res Commun 129: 701–706, 1985.

    Article  Google Scholar 

  101. Geyko F, Homma N, Suzuki Y, Arakawa M: Serum levels of 13–2 microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314: 585–586, 1986.

    Article  Google Scholar 

  102. Sethi D, Grower PE: Synovial fluid 13–2 microglobulin levels in dialysis arthropathy. N Engl J Med 315: 1419–1420, 1986.

    Article  PubMed  CAS  Google Scholar 

  103. Linker A, Carney HC: Presence and role of glycosaminoglycans in amyloidosis. Lab Invest 57: 297–305, 1987.

    PubMed  CAS  Google Scholar 

  104. Saito A, Ogawa H, Chung TG, Ohkubo I: Accumulation of serum amyloid P and its deposition in the carpal tunnel region of long-term hemodialysis patients. Trans Am Soc Artif Intern Organs 33: 512–513, 1987.

    Google Scholar 

  105. Netter P, Kessler M, Burnel D, Hutin MF, Delones S, Benoit J, Gaucher A: Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds. J Rheumatol 11: 66–70, 1984.

    PubMed  CAS  Google Scholar 

  106. Cary NRB, Sethi D, Brown EA, Erhardt CC, Woodrow DF, Gower PE: Dialysis arthropathy. Amyloid or iron? Br Med J 293: 1392–1394, 1986.

    Article  CAS  Google Scholar 

  107. Van Ypersele De Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis-related amyloidosis. Kidney Int 39: 1012–1019, 1991.

    Google Scholar 

  108. Miura Y, Ishiyama T, Inomata A, Takeda T, Senma S, Okuyama K, Suzuki Y: Radiolucent bone cysts and type of dialysis membrane used in patients undergoing long-term hemodialysis. Nephron 60: 268–273, 1992.

    Article  PubMed  CAS  Google Scholar 

  109. Acchiardo S, Kraus AP, Jennings BR: 13–2-microglobulin levels in patients with renal insufficiency. Am J Kidney Dis 13: 70–74, 1989.

    PubMed  CAS  Google Scholar 

  110. Gejyo F, Homma N, Arakawa M: Long-term complications of dialysis: pathogenetic factors with special reference to amyloidosis. Kidney Int 43(41): S-78—S-82, 1993.

    Google Scholar 

  111. Lefebvre A, deVernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C: Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36: 1112–1118, 1989.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology Department of Internal Medicine, St. Louis University Health Sciences Center, St. Louis, MO, 63110, USA

    Esther A. Gonzalez M.D. & Kevin J. Martin M.D. (Professor of Medicine, Director)

Authors
  1. Esther A. Gonzalez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin J. Martin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Wadi N. Suki M.D. Shaul G. Massry M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gonzalez, E.A., Martin, K.J. (1998). Renal Osteodystrophy: Prevention and Management. In: Suki, W.N., Massry, S.G. (eds) Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6632-5_51

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-6632-5_51

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-6634-9

  • Online ISBN: 978-1-4757-6632-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation